Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 121.35M P/E - EPS this Y -238.50% Ern Qtrly Grth -
Income -25.72M Forward P/E -3.88 EPS next Y -11.40% 50D Avg Chg 13.00%
Sales 58.36M PEG - EPS past 5Y - 200D Avg Chg 71.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -19.00%
Recommedations 1.70 Quick Ratio 6.90 Shares Outstanding 91.06M 52W Low Chg 201.00%
Insider Own 5.03% ROA -10.88% Shares Float 79.98M Beta 2.84
Inst Own 47.79% ROE - Shares Shorted/Prior 10.79M/10.37M Price 2.17
Gross Margin 68.49% Profit Margin -44.07% Avg. Volume 642,427 Target Price 8.81
Oper. Margin 0.27% Earnings Date Nov 4 Volume 563,562 Change -3.12%
About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Aquestive Therapeutics, Inc. News
08/22/24 Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
08/14/24 Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
08/08/24 Aquestive Therapeutics Second Quarter 2024 Earnings: Beats Expectations
08/06/24 Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
08/06/24 Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
08/06/24 Aquestive Therapeutics: Q2 Earnings Snapshot
08/06/24 Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
07/30/24 Institutions profited after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap rose US$72m last week but retail investors profited the most
07/25/24 Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
07/23/24 Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
07/11/24 New Strong Sell Stocks for July 11th
06/27/24 Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
06/25/24 Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
06/25/24 Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
06/19/24 Investors in Aquestive Therapeutics (NASDAQ:AQST) have unfortunately lost 36% over the last five years
06/18/24 Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
06/03/24 Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
05/28/24 Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
05/24/24 5 Small Drug Stocks to Buy From a Recovering Industry
05/09/24 Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript
AQST Chatroom

User Image precise Posted - 10 hours ago

$AQST $XBI Historically biotechs will trade significantly higher post rate cut. (Plus for AQST some near term catalysts)

User Image shaveapenny Posted - 15 hours ago

$AQST Presentations start next week. Investor day is coming (which should include new info on AQST 108). Also, Phase 3 results should release in Q4 for Anaphylm, We then proceed to file for FDA approval date. I predict as NEFFY hits the market, there is room for the AQST’s SP to move up significantly as the epi-pen alternatives makes the national news . Again, NEFFY success will only grow interest for AQST. Think about it, the entire company value is now equal to the cost of one Boeing 777 300 ER commercial jet. To compare, American Airlines owns 20 of these jets in therir fleet. I am convinced the market cap is too low, which means we have a high probability to be bought out before 109 ever reaches approval. Confirming, I added 12% to my position yesterday.

User Image Outrageous Posted - 18 hours ago

$AQST it’s happening fellow longs, check this out:

User Image Outrageous Posted - 18 hours ago

$AQST This is getting interesting. On September 5th Aquestive posted this new job: Direct to Consumer (DTC) Marketing Director Job Category: Marketing https://recruiting.ultipro.com/AQU1000AQUE/JobBoard/8a380b89-3c6f-4511-8697-2fe5c64de6ac/OpportunityDetail?opportunityId=1e7883a2-99eb-40a9-a963-7fe1db975a32

User Image SHADOWxGAINZ Posted - 1 day ago

$AQST $SPRY lol 😂 😂😂😂😂😂😂 how’s that King treatment going for you mister man?

User Image SHADOWxGAINZ Posted - 1 day ago

$AQST why it red

User Image nomas Posted - 1 day ago

$AQST interesting how movement can be tranquil. Like watching the waves roll through. I think we need some tranquility here on the upside.

User Image BiotechPsycho Posted - 1 day ago

$AQST Closed right above the SMA20.

User Image h8ster Posted - 1 day ago

$AQST Not bad for the shortened week considering it was one of the worst market weeks over the last year. Closed last week at $4.53, ended this week at $4.18. Down $0.35, or around mid -7% ish. And, the good news out of it all, is our daily RSI has been reset to the mid 50's. We are still up 23% over the last month and are no longer considered overbought. We held the $4's as we move into next week with 2 major conferences. I don't expect much from the conferences in terms of price action. They rarely provide any volume. Why? They say nothing new. They just repeat already known info. But they are telling it to new people. The main purpose of these things is create awareness. To get it on the radar of new, bigger than average market players, with the hopes they will eventually. make some purchases. These sell days are opportunities to buy the dip for those accumulating. Given the volatility of September, its best to accumulate in small blocks

User Image Falcones Posted - 1 day ago

$AQST Considering markets this is holding pretty strong! Can’t wait for upcoming catalysts. It’s going to be a wild ride and everyday management is getting closer to getting Anaphylm to the finishline.🚀

User Image prototyper Posted - 1 day ago

$AQST Better than ETFs

User Image InnerVoice Posted - 1 day ago

$AQST Bought more down here because i think we will be over 5 by end of month.

User Image n44 Posted - 1 day ago

$AQST The stock price is definitely holding up well for a Friday and the September bad news month for the stock market. I am hopeful we get a bunch of good news starting Monday.

User Image nomas Posted - 1 day ago

$AQST f-ing macro bs. buying.

User Image Lilwopjob Posted - 1 day ago

$IOVA $AQST Ugh, I’m not worried. I am bored.

User Image Optimisticinvestor777 Posted - 1 day ago

$AQST

User Image TIG2 Posted - 1 day ago

$AQST From a Spry vs Aqst it's looking like Aqst is starting to show the upper hand...IMHO just watching the share price of both...

User Image Acemaker12 Posted - 1 day ago

$AQST If I were AQST, when ANAPHYLM™* gets approved, I would do direct side by side comparisons vs neffy in its promotions.

User Image ronnie3369 Posted - 1 day ago

$AQST ...Now that the U.S. Payroll Data is Out and Actually Came in Lower than Expected...Maybe .50 Cut Instead of .25.....

User Image Stone52 Posted - 1 day ago

$AQST last trading day before Monday’s 8:30am east coast time presentation.

User Image shaveapenny Posted - 1 day ago

$AQST ‘If you go below $4, I buy more” You guys didn’t know Batman was a poet!

User Image RoyMunson69 Posted - 2 days ago

$AQST Looking forward to the analverse platform.

User Image Kiblitzer Posted - 2 days ago

$AQST Where will you be this coming Monday at 8:30 AM EST? https://investors.aquestive.com/events/event-details/hc-wainwright-26th-annual-global-investor-conference

User Image n44 Posted - 2 days ago

$AQST Obviously there is little or no volume, everyone is waiting for the conference on Monday. There should be a blast of newsworthy events coming this month, holding onto our shares for big gains.

User Image prototyper Posted - 2 days ago

$AQST Seems calm before the storm.

User Image h8ster Posted - 2 days ago

$AQST Can't remember the last time volume was this low. Forcing sellers to market sell the bid. LMAOF

User Image RCaptain Posted - 2 days ago

$AQST Where's our little bid dumper? Here fishy fishy.

User Image ronnie3369 Posted - 2 days ago

$AQST ...Volume is Pathetic Today....I has to Check and See if this was Halted...lol

User Image fda_tracker Posted - 2 days ago

$AQST Phase 2 trial w/est Sep completion date NCT06527937: https://www.clinicaltrials.gov/study/NCT06527937 Trial Tracker: https://www.fdatracker.com/trial-tracker/

User Image Outrageous Posted - 2 days ago

$AQST Are they ready for the Adrenavers Platform? Lotions, Creams, and Ointment Manufacturing Aquestive has solution mixing experience focused on the production of both pharmaceutical and over-the-counter products for a variety of vendors. With different mix platforms and different sized mix tanks from 12 gallons to 500 liters, we can seamlessly manufacture products from pilot scale to commercial scale. Our expertise in mixing products enables us to maintain the homogeneity of all ingredients throughout the mixing process. Beginning with analytical and formulation development, our team’s experts complete all phases of production within our FDA-approved facilities, while following the strictest FDA requirements to achieve the desired therapeutic effect. https://aquestive.com/services/

Analyst Ratings
HC Wainwright & Co. Buy Aug 14, 24
JMP Securities Market Outperform Aug 12, 24
HC Wainwright & Co. Buy Jul 26, 24
JMP Securities Market Outperform Jun 26, 24
HC Wainwright & Co. Buy Jun 5, 24
Leerink Partners Outperform May 10, 24
HC Wainwright & Co. Buy May 9, 24
HC Wainwright & Co. Buy Apr 30, 24
Piper Sandler Overweight Apr 11, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Boyd Peter E. SVP-Bus. Process & I.. SVP-Bus. Process & Info. Tech. Jun 14 Buy 0.81 5,000 4,050 59,532 06/15/22
Barber Daniel Chief Executive Offi.. Chief Executive Officer Jun 08 Buy 0.96 91,743 88,073 193,702 06/10/22
Schobel Alexander Mark Chief Innovation/Tec.. Chief Innovation/Tech Officer Jun 08 Buy 0.96 45,871 44,036 882,871 06/10/22
Boyd Peter E. SVP-Bus. Process & I.. SVP-Bus. Process & Info. Tech. Jun 08 Buy 0.96 2,293 2,201 54,532 06/10/22
BRAENDER LORI J General Counsel General Counsel Jun 08 Buy 0.96 13,761 13,211 38,761 06/10/22
Schobel Alexander Mark Chief Innovation/Tec.. Chief Innovation/Tech Officer Feb 10 Sell 6.75 35,000 236,250 837,000 02/10/21